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Cannabinoid receptors mediate the actions of D9-tetrahydrocannabinol (D9-THC)1 and other cannabimimetic ligands (1).
To date, two types of cannabinoid receptors have been discovered, CB1 (2, 3) and CB2 (4). A splice variant of CB1, termed
CB1A, has also been reported (5). Apart from a recent report of
CB2 in mouse cerebellum (6), CB1 has been the only cannabinoid receptor found in brain. All cannabinoid receptors discovered to date belong to the superfamily of G-protein-coupled
receptors (3, 4); their effectors include inhibition of adenylyl
cyclase (7, 8), inhibition of calcium influx (9), and activation of
inwardly rectifying potassium channels (10, 11). The physiological actions of cannabinoid ligands have been shown to be
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mediated through the activation of pertussis toxin-sensitive
G-proteins (Gia and Goa subtypes) (7, 12), although some effects have been implicated via Gsa as well (13, 14).
G-proteins are heterotrimeric proteins that transduce the
agonist binding signal from G-protein-coupled receptors to effectors (15, 16). Upon activation by an agonist-occupied receptor, the a subunit of a G-protein (Ga) releases bound GDP,
binds a molecule of GTP, and dissociates from the G-protein bg
subunit complex. Both Ga and bg subunits act upon effectors
until Ga cleaves the bound GTP to GDP by its intrinsic GTPase
activity, and Ga re-associates with a bg dimer (15, 16). The
cycle is then complete, and the heterotrimeric G-protein is able
to be activated again. Receptors act catalytically, as one receptor can activate multiple G-proteins (17–19). The activation
and dissociation of the G-protein subunits occur very rapidly
and thus do not appear to be rate-limiting steps in the signal
transduction cascade (20). However, since the actions of G-protein-coupled receptors are mediated strictly via the activation of
G-proteins, this step plays a key role in determining overall
agonist efficacy (21) and may be the most relevant step in measuring agonist efficacy at G-protein-coupled receptors (22).
Agonist-stimulated binding of the hydrolysis-resistant GTP
analog, [35S]GTPgS, to G-protein a subunits measures receptor
activation of G-proteins in purified and reconstituted systems
(23), native cell membrane preparations (24), and brain sections (25). The present study focuses on three aspects of the role
of GDP in the agonist-stimulated [35S]GTPgS binding assay.
First, GDP has been shown to decrease basal [35S]GTPgS binding and allow detection of agonist stimulation. The requirement for micromolar concentrations of GDP to observe agonist
effects in native membrane preparations has been reported
consistently in every system for which agonist-stimulated
[35S]GTPgS binding has been demonstrated (24, 26 –28). Second, GDP has been reported to modulate the kinetics of
[35S]GTPgS binding. The presence of micromolar concentrations of GDP was shown to decrease the magnitude and rate of
[35S]GTPgS binding to purified and reconstituted G-proteins
(23). However, early reports of [35S]GTPgS binding to purified
G-protein Gia (29) and Goa (30) subunits concluded that this
binding is essentially irreversible in the presence of millimolar
concentrations of Mg21, which is also required for agonist stimulation of [35S]GTPgS binding (31). Therefore, a problem frequently noted for [35S]GTPgS binding is that it is performed
under non-equilibrium conditions, thus complicating interpretation of the results.
Finally, GDP has been shown to play an important role in
determining agonist efficacy for the stimulation of [35S]GTPgS
binding. In the adenosine A1 receptor system, a full agonist
was shown to be maximally effective for the stimulation of
[35S]GTPgS binding at a higher concentration of GDP than a
partial agonist (32). Similar results were found in the mu
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The relationship between GDP and cannabinoid-stimulated [35S]guanosine-5*-O-(3-thiotriphosphate) ([35S]GTPgS) binding was investigated in rat cerebellar
membranes. Kinetic analyses showed that [35S]GTPgS
binding reached steady-state levels and that the association rate was increased by the agonist WIN 55212-2
proportional to the concentration of GDP. Dissociation
of [35S]GTPgS occurred with two rates (t1⁄2 5 7 and 170
min), and WIN 55212-2 increased the proportion of sites
exhibiting the faster rate. Without GDP, [35S]GTPgS
bound to membranes with high and low affinity, and
WIN 55212-2 had no effect. With 30 mM GDP, [35S]GTPgS
bound to low and intermediate affinity sites, and WIN
55212-2 induced high affinity [35S]GTPgS binding without affecting low affinity sites. GDP competed for high
affinity [35S]GTPgS binding with high and intermediate
affinity in the absence of WIN 55212-2 and with high and
low affinity in the presence of WIN 55212-2. Cannabinoid
ligands displayed differential abilities to maximally
stimulate [35S]GTPgS binding in the presence of GDP.
Efficacy differences among ligands increased with increasing GDP concentrations. GDP competition curves
revealed that agonists induced low affinity GDP Ki
values that were proportional to agonist Emax values,
indicating that agonist efficacy is determined by displacement of GDP from G-proteins.
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opioid system, where increasing the concentration of GDP increased relative efficacy differences among agonists (33). In
order to determine whether GDP plays similar roles in modulating cannabinoid agonist efficacy, it is necessary to compare
[35S]GTPgS binding stimulated by agonists of different efficacies. Previous studies which showed that D9-THC (34, 35), CP
55940 (36), and anandamide (37–39) are each partial agonists
provide an effective starting point to examine this question.
The present study explores these three aspects of GDP modulation of G-protein activation by cannabinoid agonists. The
cannabinoid system is ideal for the study of G-protein activation in brain membranes, due to the very high levels of cannabinoid receptors (40) and cannabinoid-activated G-proteins (25)
compared with other G-protein-coupled receptors in brain.
These experiments provide evidence that cannabinoid agoniststimulated [35S]GTPgS binding is dependent on the agonistinduced decrease in G-protein affinity for GDP and that cannabinoid agonist efficacy for G-protein activation is determined
by the magnitude of this decrease in affinity.
EXPERIMENTAL PROCEDURES

B 5 Bfinal 3 ~1 2 e2kt!

(Eq. 1)

where B is the amount of [35S]GTPgS bound at time t; Bfinal is the
maximum amount of ligand bound under steady-state conditions, and k
is the apparent association rate constant (kobs). Dissociation parameters
were determined by fitting for biphasic bimolecular dissociation as
shown in Equation 2 (43).
B 5 B01 3 e2k1t 1 B02 3 e2k2t

(Eq. 2)

where B is the amount of [ S]GTPgS bound at time t; B01 and B02 are
the amounts of ligand bound to rapidly and slowly dissociating sites at
time 0, and k1 and k2 are the dissociation rate constants (k21) for the
rapidly and slowly dissociating sites, respectively. Half-times for each
site were calculated by dividing 2ln(0.5) by the respective rate constants (kobs or k21). EC50 and Emax values for each agonist were determined by fitting concentration-effect curves to Equation 3.
35

[L] 3 Emax
[L]1EC50

(Eq. 3)

where E is amount of [ S]GTPgS bound at receptor ligand concentration [L]; Emax is the amount of [35S]GTPgS bound at maximally effective
concentrations of receptor ligand, and EC50 is the concentration of
receptor ligand producing half-maximal [35S]GTPgS binding. IC50 and
Imax values for GDP competition curves were determined by fitting the
biphasic Equation 4.
35

I5

@I# 3 Imax(H0 @I# 3 Imax(L)
1
@I# 1 IC50(H) @I# 1 IC50(L)

(Eq. 4)

where I is the amount of [35S]GTPgS binding inhibited at GDP concentration [I]; Imax(H) and Imax(L) are the maximum amounts of [35S]GTPgS
inhibited from either the high or low affinity sites, respectively, and
IC50(H) and IC50(L) are the concentrations of GDP that inhibit half of the
[35S]GTPgS binding from each site, respectively. Ki values were estimated by the Cheng-Prusoff equation (44). [35S]GTPgS saturation binding was analyzed using EBDA and LIGAND (45) to determine apparent
high and low affinity Bmax and KD values. Significant differences (p ,
0.05) among values were determined using JMP to perform a two-tailed
Tukey-Kramer HSD test for multiple comparisons or a two-tailed Student’s t test to compare two values. Unless otherwise indicated, all data
presented are mean 6 S.E. of three or more determinations from assays
that were each performed in triplicate.
RESULTS

Effects of GDP and Cannabinoid Agonist on the Kinetics of
[35S]GTPgS Binding—The association and dissociation rates of
[35S]GTPgS binding were investigated in rat cerebellar membranes using different concentrations of GDP, in the presence
and absence of a maximally effective concentration of the cannabinoid agonist WIN 55212-2. Fig. 1A shows association of
[35S]GTPgS binding; Table I provides maximal binding and t1⁄2
values of association under these conditions. [35S]GTPgS binding to cerebellar membranes reached steady state at a rate that
was dependent on the concentration of GDP. At 0 and 0.1 mM
GDP, [35S]GTPgS binding reached maximum values within 1
and 2 h, respectively, and actually decreased slightly between
2 and 4 h. Maximal [35S]GTPgS binding, both in the presence
and absence of agonist, was decreased by increasing concentrations of GDP. Stimulation by WIN 55212-2 could only be observed with micromolar concentrations of GDP, and the percent stimulation of [35S]GTPgS binding by agonist was
increased by increasing concentrations of GDP, up to a maximum of 125% at 30 mM GDP (Table I).
Both GDP and agonist significantly affected the rate of
[35S]GTPgS association, as determined by the apparent t1⁄2 values (Table I). As the concentration of added GDP was increased
from 0 to 30 mM, t1⁄2 values of basal [35S]GTPgS association were
increased from 8.5 to 101 min. The effect of agonist was increased by GDP; addition of WIN 55212-2 had no effect on the
t1⁄2 of association in the absence of GDP but significantly decreased the t1⁄2 from 101 to 72 min at 30 mM GDP.
Data for dissociation of [35S]GTPgS binding are shown in
Fig. 1B as percent of steady-state binding values obtained in
the presence or absence of agonist at each concentration of
GDP. Actual binding values at time 0 were very similar to
those obtained under the same conditions at 2 h in the association assays (Fig. 1A). In contrast to previous reports of irreversible binding of [35S]GTPgS to purified G-proteins in the
presence of millimolar concentrations of Mg21 (29, 30),
[35S]GTPgS dissociated with both a rapid (t1⁄2 of 6.8 min) and a
slow (t1⁄2 of 170 min) dissociation rate from cerebellar membranes. The biphasic nature of [35S]GTPgS dissociation is
shown by the logarithmic plot of the data in Fig. 1B. Nonlinear
regression analysis of these data determined that neither GDP
nor agonist affected the t1⁄2 values of either rate, but both
increased the fraction of sites that displayed rapid dissociation.
In the absence of GDP and agonist, only 14% of the
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Materials—Male Sprague-Dawley rats were purchased from Zivic
Miller (Zelienople, PA). [35S]GTPgS (1250 Ci/mmol), and ReflectionsTM
film were obtained from NEN Life Science Products. Anandamide,
(R)-(1)-methanandamide and WIN 55212-2 were purchased from Research Biochemicals International (Natick, MA). CP 55940 and levonantradol were obtained from Pfizer, Inc. (Groton, CT). D9-THC was
provided by NIDA/Research Triangle Institute (Research Triangle
Park, NC). SR141716A was a generous gift from Dr. Francis Barth at
Sanofi Recherché (Montpellier, France). Guanosine diphosphate (GDP)
and unlabeled GTPgS were purchased from Boehringer Mannheim. All
other reagent grade chemicals were obtained from Sigma or Fisher.
Membrane Preparations—Rat cerebellar membranes were prepared
in membrane buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, pH
7.4) and stored at 280 °C as described previously (41). For assays
including anandamide, thawed membranes were pretreated with 50 mM
phenylmethylsulfonyl fluoride (PMSF) followed by centrifugation and
homogenization of the pellet. All preparations were preincubated for 10
min at 30 °C with 0.004 units/ml adenosine deaminase (Sigma) and
assayed for protein content (42) before addition to assay tubes.
[35S]GTPgS Binding—Assays were performed as described previously (41). Unless otherwise specified, 4 –15 mg of cerebellar membrane
protein were incubated for 2 h at 30 °C in membrane buffer containing
0.1% (w/v) bovine serum albumin, 100 mM NaCl, 30 mM GDP, and 0.05
nM [35S]GTPgS in a final volume of 1 ml, and nonspecific binding was
determined with 30 mM unlabeled GTPgS. For association assays, membranes were added to assay tubes on ice, and assay tubes were transferred to a 30 °C water bath at various times. Reactions were terminated in all tubes simultaneously by rapid filtration as described
previously (41). For dissociation assays, assay tubes were allowed to
associate for 1 h (0 and 0.1 mM GDP) or 2 h (3 and 30 mM GDP) before
the addition of 30 mM unlabeled GTPgS at various times; reactions were
terminated as above.
Data Analysis—Unless otherwise indicated, binding parameters
were determined by nonlinear regression analysis using JMP for
Macintosh (SAS Institute, Cary, NC). Association parameters were
fitted to Equation 1 (43).
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TABLE I
Association and dissociation of [35S]GTPgS binding
Kinetics of [35S]GTPgS binding to cerebellar membranes were determined in the absence (basal) and presence of WIN 55212–2 at different
concentrations of GDP, as shown in Fig. 1. Kinetic values were obtained
by nonlinear fitting of the data, as described under “Experimental
Procedures.” “% of fast dissociating sites” is the percentage of
[35S]GTPgS-binding sites that exhibited a rapid dissociation rate (t1⁄2 5
6.8 min) versus a slow dissociation rate (t1⁄2 5 170 min). Letters indicate
a significant effect of GDP; values within a column designated with
different letters are significantly different (p , 0.05) by the TukeyKramer test.
Maximum binding
[GDP]

1 3 mM WIN 55212–2

Basal

mM

Association
0
0.1
3
30

pmol/mg

1.502 6 0.032 a
0.997 6 0.069 b
0.571 6 0.023 c
0.246 6 0.014 d

1.524 6 0.029 a
1.080 6 0.048 b
0.865 6 0.021 ca
0.548 6 0.035 da
Apparent t1⁄2
min

8.5 6 0.2 a
22 6 0.3 ab
60 6 6.8 b
101 6 16 c

8.4 6 0.4 a
19 6 0.5 a
45 6 3.4 ab
72 6 7.4 ba

% fast-dissociating sites

Dissociation
0
0.1
3
30

14 6 1.0 a
23 6 2.1 ab
22 6 2.8 ab
27 6 1.8 b

25 6 0.5a
38 6 5.0a
41 6 6.9a
44 6 2.7a

a
Significant effects of WIN 55212–2 at a given GDP concentration
are p , 0.05 by Student’s t test.

FIG. 1. Effects of GDP and WIN 55212-2 on the association and
dissociation of [35S]GTPgS binding in rat cerebellar membranes. For association assays (A), membranes were incubated at
30 °C for various times with 0.05 nM [35S]GTPgS in the presence of
various concentrations of added GDP and in the presence and absence
of 3 mM WIN 55212-2. B depicts dissociation assays that were conducted
by incubating membranes for 1–2 h under the same conditions used for
the association assays before the addition of 30 mM unlabeled GTPgS at
various times. Data in B are expressed on a logarithmic scale as percent
of steady-state [35S]GTPgS binding.

[35S]GTPgS-binding sites exhibited the rapid dissociation rate
(Table I). Increasing the concentration of GDP alone increased
the fraction of rapidly dissociating binding sites to 27% of total
[35S]GTPgS binding at 30 mM GDP. Unlike the effects of WIN
55212-2 on [35S]GTPgS association, WIN 55212-2 significantly
affected dissociation regardless of the concentration of GDP,
increasing the fraction of rapidly dissociating sites to 25% in
the absence of GDP up to 44% with 30 mM GDP. Moreover,
although there was a significant increase in the dissociation by
30 mM GDP in the absence of agonist, the effect of GDP in the
presence of WIN 55212-2 did not reach statistical significance.
Net agonist-stimulated [35S]GTPgS binding kinetics are
shown in Fig. 2. These curves were obtained by subtracting
basal binding values from the values obtained in the presence
of WIN 55212-2 at each respective time point and GDP concentration. Since there was significant stimulation by WIN
55212-2 only at micromolar GDP concentrations, net agoniststimulated [35S]GTPgS association and dissociation are shown
for 3 and 30 mM GDP. In Fig. 2, it can be seen that net WIN
55212-2-stimulated [35S]GTPgS binding reaches steady-state
levels within 2 h and is readily dissociable.
Effects of GDP and Cannabinoid Agonist on Steady-state
[35S]GTPgS Binding Parameters—To characterize [35S]GTPgSbinding sites and the effect of agonist on these sites, GTPgS

FIG. 2. Effects of GDP on net WIN 55212-2-stimulated
[35S]GTPgS binding to rat cerebellar membranes. Net agoniststimulated [35S]GTPgS binding was determined from the data shown in
Fig. 1 by subtracting basal [35S]GTPgS binding values from values
obtained in the presence of WIN 55212-2 at each time point.

saturation experiments were performed after 2-h incubations
in the presence and absence of a maximally effective concentration of WIN 55212-2 and 30 mM GDP (Fig. 3). In the absence
of GDP, [35S]GTPgS binding was biphasic, displaying both high
(apparent KD 5 2.7 nM) and low (apparent KD 5 800 nM)
affinity sites (Table II). Addition of WIN 55212-2 had no effect
on the apparent KD or Bmax of either site in the absence of GDP
(Fig. 3A). In the presence of 30 mM GDP alone (Fig. 3B),
[35S]GTPgS binding was best fit to sites with intermediate
(apparent KD 5 14 nM) and low affinity; apparent Bmax values
were decreased by 70 – 80% compared with those in the absence
of added GDP. Addition of agonist with 30 mM GDP produced
[35S]GTPgS binding with high (apparent KD 5 4 nM) and low
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TABLE II
[35S]GTPgS binding parameters in rat cerebellar membranes
Apparent Bmax and KD values were determined using 0.05 nM
[35S]GTPgS plus 0.5 nM to 10 mM unlabeled GTPgS in the absence and
presence of 3 mM WIN 55212–2, to determine basal and agonist-stimulated binding, respectively. (H) designates KD and Bmax values for high
affinity binding sites, (L) indicates low affinity sites, and (I) indicates
intermediate affinity sites. Assays were conducted in the absence and
presence of 30 mM added GDP. Net agonist-stimulated [35S]GTPgS
binding, determined by subtracting basal from WIN 55212–2-stimulated [35S]GTPgS binding at each concentration of GTPgS, was not
detectable (N/A, not applicable) in the absence of GDP and was
monophasic and high affinity in the presence of GDP.
No GDP
Basal

1 3 mM WIN 55212–2

Net

KD(H) (nM)
Bmax(H) (pmol/mg)
KD(L) (nM)
Bmax(L) (pmol/mg)

2.7 6 1.1
110 6 33
750 6 110
1060 6 220

3.0 6 1.1
120 6 33
920 6 180
1140 6 430

N/A
N/A
N/A
N/A

KD(I/H) (nM)
Bmax(I/H) (pmol/mg)
KD(L) (nM)
Bmax(L) (pmol/mg)

14 6 2.2
15 6 3.8
540 6 104
220 6 56

30 mM GDP

2.7 6 0.3
12.6 6 1.1
N/A
N/A

By Student’s t test, p , 0.05 for WIN 55212–2 versus basal.

FIG. 3. Effect of GDP and WIN 55212-2 on [35S]GTPgS-binding
sites in rat cerebellar membranes. Representative biphasic Scatchard plots of [35S]GTPgS binding with and without 3 mM WIN 55212-2
in the absence (A) and presence (B) of 30 mM GDP. Saturation binding
was accomplished by incubating membranes at 30 °C for 2 h with 0.05
nM [35S]GTPgS plus 0.5 nM to 10 mM unlabeled GTPgS. B, inset, Scatchard plot of net agonist-stimulated [35S]GTPgS binding determined by
subtracting basal [35S]GTPgS binding from that obtained in the presence of WIN 55212-2 at each concentration of GTPgS. Data shown are
representative of three experiments that gave similar results; mean
apparent KD and Bmax values are given in Table II.

affinity sites (Fig. 3B). The apparent KD and Bmax values of the
low affinity sites were not significantly affected by agonist. The
apparent KD of the agonist-induced high affinity (4 nM) site was
significantly lower than the apparent KD of the intermediate
affinity (14 nM) site of basal [35S]GTPgS binding (p 5 0.010);
however, there was no significant different between the Bmax
values of these sites. Whereas there was no net agonist-stimulated [35S]GTPgS binding in the absence of added GDP (Fig.
3A), net WIN 55212-2-stimulated [35S]GTPgS binding in the
presence of GDP was monophasic with an apparent high
affinity KD value of 2.7 nM (Fig. 3B, inset, and Table II),
similar to previous results with mu and delta opioid agonists
(19, 27, 33, 46).
In addition to increasing the apparent affinity of Ga for
[35S]GTPgS, agonists have been reported to reduce the affinity
of Ga for GDP (15, 16, 23). To explore this possibility, cerebellar
membranes were incubated with [35S]GTPgS and 0.3 nM to
1000 mM GDP in the presence and absence of WIN 55212-2 (Fig.
4). Since the standard concentration of [35S]GTPgS used (0.05
nM) results in low occupancy of high affinity [35S]GTPgS-binding sites (0.5–2%), these assays were also conducted using two
higher concentrations of [35S]GTPgS (0.2 and 1 nM) to produce
approximately 7 and 25% occupancy of the high affinity sites.
Nevertheless, at any of these concentrations of [35S]GTPgS,

FIG. 4. Effect of WIN 55212-2 on competition binding of
[35S]GTPgS and GDP in rat cerebellar membranes. Membranes
were incubated with 0.05, 0.20, or 1.0 nM [35S]GTPgS plus 0.3 nM to 1
mM GDP in the presence and absence of 3 mM WIN 55212-2. B, data
from A re-plotted on a logarithmic scale y axis to show the effect of WIN
55212-2 at low levels of [35S]GTPgS binding. GDP Ki and Imax values are
provided in Table III.

high affinity [35S]GTPgS binding would predominate, since 1
nM [35S]GTPgS would occupy less than 0.15% of the low affinity
sites. Thus, the GDP-binding sites investigated under these
conditions represented only sites that bound [35S]GTPgS with
high affinity.
The results showed that as cannabinoid agonist increased
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a

4.0 6 0.7a
23 6 3.8
980 6 270
350 6 68
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TABLE III
Parameters of GDP competition for high affinity [35S]GTPgS
binding in rat cerebellar membranes
Imax and IC50 values were determined by displacement of 0.05, 0.2, or
1.0 nM [35S]GTPgS by 0.3 nM to 1 mM GDP in the presence and absence
of 3 mM WIN 55212–2. (H), (I), and (L) designate Ki and Imax values for
high, intermediate, and low affinity binding sites, respectively. Ki values were calculated from IC50 values as described under “Experimental
Procedures.”
Basal
0.05 nM GTPgS

Ki(H) (nM)
Imax(H) (pmol/mg)
Ki(I) (nM)
Imax(I) (pmol/mg)

28 6 7.9
1.35 6 0.14
764 6 182
0.70 6 0.11

Ki(H) (nM)
Imax(H) (pmol/mg)
Ki(L) (nM)
Imax(L) (pmol/mg)

38 6 13
1.29 6 0.13
6800 6 1320a
0.82 6 0.09

0.2 nM GTPgS

31 6 8.6
5.32 6 0.56
1050 6 266
3.10 6 0.22

1.0 nM GTPgS

20 6 1.6
13.1 6 0.85
854 6 116
12.6 6 1.5

1 3mM WIN 55212–2

a

38 6 7.9
4.88 6 0.38
7600 6 1290a
3.24 6 0.28

31 6 11
15.5 6 1.2
6930 6 469a
9.90 6 0.23

By Student’s t test, p , 0.01 for WIN 55212–2 versus basal.

[35S]GTPgS binding, concentration-effect curves were generated in the presence of 30 mM GDP (Fig. 5). Some of the agonists
exhibited shallow concentration-effect curves, indicating stimulation of [35S]GTPgS binding by more than one site (or affinity
state of the receptor). Since this study focused on differences in
the maximal stimulation of [35S]GTPgS binding by each agonist, concentration-effect curves were analyzed for EC50 and
Emax values monophasically. Full biphasic analysis of agonist
stimulation of [35S]GTPgS binding will be conducted in a future
study. Potencies (EC50 values) varied widely for these compounds. CP 55940 displayed the greatest potency with an EC50
of 6.6 6 0.5 nM; levonantradol was next at 9.0 6 0.4 nM,
followed by D9-THC at 87 6 42 nM, WIN 55212-2 at 160 6 38
nM, and methanandamide and anandamide at 320 6 26 and
390 6 96 nM, respectively (Fig. 5). As previously shown for
receptor binding (39), pretreatment of the membranes with the
irreversible esterase inhibitor PMSF greatly increased the potency of anandamide, since without PMSF pretreatment, anandamide stimulated [35S]GTPgS binding with an EC50 of 1750 6
570 nM (data not shown). In contrast, none of the potencies or
efficacies of the other agonists, including methanandamide,
were significantly affected by PMSF pretreatment (data not
shown).
Concentration-effect analysis revealed that these ligands
produced a wide range of efficacies for G-protein activation in
the [35S]GTPgS binding assay (Fig. 5). WIN 55212-2 and levonantradol displayed the highest efficacies, and these two ligands were designated as full agonists. For this reason, results
for other ligands were normalized to the amount of net agoniststimulated [35S]GTPgS binding obtained with a maximally effective concentration of levonantradol (1 mM), which was defined as 100% within each experiment (Fig. 5). Likewise, Emax
values obtained by nonlinear regression analysis for each agonist were normalized to the Emax value obtained with levonantradol (Table IV). Whereas the Emax value of WIN 552122-stimulated [35S]GTPgS binding (106 6 2%) was not
significantly different from that of levonantradol, CP 55940
acted as a high efficacy partial agonist stimulating 81 6 2% as
much as levonantradol. Anandamide and methanandamide
each produced Emax values of approximately 70% (70 6 6 and
68 6 2%, respectively) of levonantradol. In agreement with
previous results (34, 35), D9-THC stimulated only 21 6 0.7% as
much as levonantradol, confirming that this ligand exhibits
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the apparent affinity of a fraction of [35S]GTPgS-binding sites
(Fig. 3), it also decreased the affinity of a fraction of GDPbinding sites (Fig. 4). The effect of agonist on GDP affinity in
Fig. 4A is best observed for the upper set of curves (1 nM
[35S]GTPgS), where significant increases in binding by WIN
55212-2 were not observed until GDP concentrations exceeded
0.1 mM. To show that this effect of agonist was also observed at
lower concentrations of [35S]GTPgS (0.05 and 0.20 nM), these
data were re-plotted in a logarithmic fashion (Fig. 4B). When
plotted in this manner, it is clear that WIN 55212-2 had no
effect on [35S]GTPgS binding at low (,0.1 mM) concentrations of
GDP but increased binding in the presence of micromolar concentrations (1–100 mM) of GDP, i.e. WIN 55212-2 shifted the
lower affinity component of the GDP competition curve to the
right. Nonlinear regression analysis showed that GDP inhibited basal [35S]GTPgS binding in a biphasic manner, with high
affinity Ki values of 20 –30 nM and intermediate affinity Ki
values of 800 –1000 nM, regardless of the [35S]GTPgS concentration used (Table III). In the presence of WIN 55212-2, GDP
competed for [35S]GTPgS binding with high affinity (Ki of
30 – 40 nM) and low affinity (Ki of 7000 nM). These data show
that high affinity Ki values for GDP in the presence of WIN
55212-2 were indistinguishable from those measured under
basal conditions but that the agonist-induced low affinity Ki
value was 8-fold lower than the intermediate affinity component observed under basal conditions. Although high affinity
GDP sites represented approximately 60% of the total high
affinity basal [35S]GTPgS-binding sites, variability in the Imax
calculations prevented any definitive determination of agonistinduced changes in the proportion of high affinity GDP-binding
sites.
Relationship between GDP and Cannabinoid Agonist Efficacy—Previous studies have demonstrated differences in cannabinoid agonist efficacies by different methods. Since G-protein
activation is the first step in the signal transduction cascade of
G-protein-coupled receptors, it was of interest to measure cannabinoid efficacy by agonist-stimulated [35S]GTPgS binding.
Several cannabinoid ligands with different structural bases
were selected including the following: D9-THC, the primary
psychoactive constituent of marijuana; WIN 55212-2, a synthetic aminoalkylindole agonist; levonantradol, a potent D9THC analog; CP 55940, a synthetic bicyclic compound; anandamide and methanandamide, an endogenous cannabinoid agonist and its esterase-resistant analog; and SR141716A, the
CB1-selective antagonist.
To establish the relative efficacies of these agonists for

FIG. 5. Concentration-effect curves of cannabinoid ligands in
stimulating [35S]GTPgS binding to rat cerebellar membranes.
Membranes were incubated with 0.05 nM [35S]GTPgS, 30 mM GDP, and
various concentrations of each ligand. Data are expressed as the percent of [35S]GTPgS binding obtained in the presence of a maximally
effective concentration of levonantradol (1 mM), which was 190 6 45
fmol/mg. Emax values for each agonist are provided in Table IV.
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TABLE IV
Stimulation of [35S]GTPgS binding Emax and GDP Ki
values induced by cannabinoid agonists
Emax values were obtained by nonlinear regression analysis of the
stimulation of [35S]GTPgS binding by various concentrations of each
agonist, shown in Fig. 5, except the Emax value reported for 0.1 mM WIN
55212–2, which was determined by the amount of [35S]GTPgS binding
obtained with that concentration of the agonist. Data are expressed as
mean 6 S.E. of percent of the Emax value obtained with levonantradol
for each experiment. GDP Ki values were calculated from IC50 values
determined by competition of 0.05 nM [35S]GTPgS with 0.3 nM to 1 mM
GDP in the presence and absence of 3 mM WIN 55212–2, shown in Fig.
6. ND, not determined. Emax values that are not marked with the same
letter are significantly different from each other by the Tukey-Kramer
test at p , 0.05.
Cannabinoid agonist

Emax values

GDP Ki values (nM)
High affinity

Low affinity

33 6 5.1
34 6 2.3
39 6 7.6
ND
ND
33 6 5.6
20 6 6.2
47 6 5.2

1147 6 141
7730 6 1030a
8210 6 1190a
ND
ND
6570 6 2540b
1330 6 372
4210 6 900

% levonantradol

a
b

N/A
100 a
107 6 2.3 a
81 6 2.5 b
70 6 5.8 bc
68 6 2.1 c
21 6 0.7 e
44 6 3.1 d

p , 0.005 for agonist-induced versus basal GDP Ki values.
By Student’s t test, p , 0.05.

weak partial agonist activity. Finally, SR141716A failed to
stimulate [35S]GTPgS binding at any concentration, indicating
that this ligand is a pure antagonist with zero efficacy. However, SR141716A slightly but consistently inhibited basal
[35S]GTPgS binding at the highest concentration (10 mM) used
(Fig. 5).
In other receptor systems, increasing the GDP concentration
was reported to increase differences between full and partial
agonists for stimulating [35S]GTPgS binding (32, 33). Therefore, the relationship between GDP and cannabinoid agonist
efficacy was directly explored using a few representative cannabinoid ligands. To determine whether the affinity of the low
affinity GDP-binding site was related to the efficacy of the
agonist, GDP competition curves were generated with 0.05 nM
[35S]GTPgS in the presence and absence of maximally effective
concentrations of these ligands. As described above (Table III),
GDP displaced [35S]GTPgS binding with both high and intermediate affinity or high and low affinity in the absence or
presence of agonist, respectively. Full biphasic analysis (Table
IV) indicated that the agonists had no significant effect on the
Ki values of high affinity GDP binding, which were all between
20 and 47 nM. In the absence of agonist, the low affinity GDPbinding sites had an intermediate Ki value of 1.1 mM; in the
presence of agonist, the affinity of this low affinity GDP site
depended on the agonist. D9-THC had no statistically significant effect on the low affinity GDP Ki value (1.3 mM), whereas
the full agonists WIN 55212-2 and levonantradol produced low
affinity GDP Ki values of 8 mM, and the partial agonist methanandamide produced a Ki value of 6.6 mM. Addition of a submaximally effective concentration of WIN 55212-2 (0.1 mM),
which stimulated 44% of maximal [35S]GTPgS binding values,
produced an intermediate low affinity GDP Ki value of 4.2 mM
(Table IV).
The finding that these agonists decreased GDP affinity in
proportion to their efficacies predicts that saturating concentrations of full agonists will be maximally effective for the
stimulation of [35S]GTPgS binding at higher concentrations of
GDP than saturating concentrations of partial agonists. This
relationship is depicted in Fig. 6A where net agonist-stimulated [35S]GTPgS binding is plotted as a function of the concentration of added GDP. For each agonist assayed, net ago-

FIG. 6. Effect of GDP on the relative efficacies of cannabinoid
agonists in stimulating [35S]GTPgS binding to rat cerebellar
membranes. Membranes were incubated with 0.05 nM [35S]GTPgS
plus 0.3 nM to 100 mM GDP, in the presence and absence of maximally
effective concentrations of each agonist as determined by data shown in
Fig. 5. Net agonist-stimulated [35S]GTPgS binding values were determined by subtracting values obtained in the absence from those obtained in the presence of WIN 55212-2, and percent stimulation values
were determined by dividing net agonist-stimulated [35S]GTPgS binding values by basal binding values at each concentration of GDP. Data
are expressed as a percentage of the maximum values obtained with
levonantradol, which were 466 6 28 fmol/mg of net agonist-stimulated
binding and 399 6 43% stimulation.

nist-stimulated [35S]GTPgS binding increased with increasing
GDP concentrations until maximum net-stimulated binding
was achieved. The GDP concentration that produced maximal
net-stimulated binding depended on the efficacy of the agonist.
Maximal net agonist-stimulated [35S]GTPgS binding was observed with D9-THC at approximately 0.1– 0.2 mM GDP, with
methanandamide at approximately 1 mM GDP, and with WIN
55212-2 at 2–3 mM GDP. SR141716A failed to significantly
stimulate [35S]GTPgS binding at any GDP concentration, and
results for 1 mM levonantradol were similar to those obtained
with 10 mM WIN 55212-2 (data not shown). When the data were
plotted as percent stimulation by each agonist as a function of
GDP concentration (Fig. 6B), differences in percent stimulation
among the agonists increased as the concentration of GDP was
increased to an optimum level of approximately 100 mM. Thus,
at 0.1 mM GDP there was little difference between the full and
partial agonists, at 1 mM GDP there was a significant difference
between D9-THC and all of the higher efficacy agonists, and at
30 mM GDP the efficacies of the high efficacy partial agonists
CP 55940, anandamide, and methanandamide were different
from the full agonists WIN 55212-2 and levonantradol (data for
representative ligands are shown in Fig. 6B). CP 55940 was
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WIN 55212–2
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FIG. 7. Correlation between relative agonist efficacy (Emax) in
stimulating [35S]GTPgS binding and agonist-induced low affinity GDP Ki values. Data for relative agonist efficacy (agonist Emax
values) and low affinity GDP binding Ki values were obtained from
Table IV.

DISCUSSION

This study characterized several aspects of the role of GDP in
the activation of G-proteins by cannabinoid receptors in brain
membranes. In kinetics studies, [35S]GTPgS binding to cerebellar membranes reached an apparent steady state and was
readily dissociable. Moreover, cannabinoid agonist increased
the rate of both [35S]GTPgS association and dissociation. Addition of GDP decreased the rate and magnitude of [35S]GTPgS
association, consistent with the competitive binding of
[35S]GTPgS and GDP as previously shown in purified G-proteins (43).
It was significant that agonist-stimulated [35S]GTPgS binding was shown to be dissociable under these assay conditions,
which include 3 mM Mg21, and that both GDP and agonist
increased the rate of [35S]GTPgS dissociation, just as muscarinic agonists and guanine nucleotides increased the dissociation of [35S]GTPgS from native cardiac membranes (47). The
findings of reversible [35S]GTPgS binding in membranes seem
to contradict earlier studies where [35S]GTPgS binding to purified Goa and Gia was virtually irreversible in the presence of
millimolar concentrations of Mg21 (29, 30). This discrepancy
might be explained by the lower ratio of G-protein bg to Ga
subunits in purified systems compared with those that may be
present in native membranes (29, 30, 48, 49). [35S]GTPgS binding to purified Goa and Gia exhibits both rapid and slow dissociation rates, and the ratio of slowly to rapidly dissociating
sites is proportional to the concentration of Mg21 (50). bg
subunits increase the dissociation of [35S]GTPgS from Ga, but
this effect is inhibited by Mg21, which inhibits bg coupling to

Ga (30, 50). The present study found that upon addition of
excess GTPgS, cannabinoid agonist increased the ratio of rapidly to slowly dissociating [35S]GTPgS-binding sites by the
same degree (62– 86%) regardless of the concentration of GDP.
It is possible that the agonist-induced increase in rapidly dissociating [35S]GTPgS binding was the result of the liberation of
large amounts of bg by the agonist-accelerated binding of the
unlabeled GTPgS to Ga subunits. The finding that GDP produced a slight increase in the ratio of rapidly dissociating
[35S]GTPgS-binding sites is consistent with the fact that GDP
increases the ratio of low affinity to high affinity [35S]GTPgSbinding sites (Fig. 3), which would be expected to display different dissociation rates.
In cerebellar membranes, basal and cannabinoid-stimulated
[35S]GTPgS binding appeared to follow the characteristics of
bimolecular reactions, allowing the data to be analyzed in the
manner of traditional radioligand binding. However, any study
involving the binding of guanine nucleotide analogs to G-proteins must consider the presence of pre-bound GDP. It has been
shown that GDP remains bound to Ga in high molar ratios
even after purification of Ga subunits (43). Thus, all parameters of [35S]GTPgS binding to native cell membranes must be
considered “apparent” in the presence or absence of added
GDP. The present study has also demonstrated that occupancy
of 2% of high affinity [35S]GTPgS-binding sites using 0.05 nM
[35S]GTPgS accurately assesses high affinity [35S]GTPgS-binding sites, since concentrations of [35S]GTPgS that occupied up
to 25% of high affinity sites yielded identical results with
respect to the effects of GDP and agonist (Fig. 4).
Concentration-effect curves comparing the relative efficacies
of several cannabinoid agonists determined that WIN 55212-2
and levonantradol produced the highest Emax values for the
stimulation of [35S]GTPgS binding and are therefore referred
to as full agonists. CP 55940 was a high efficacy partial agonist,
confirming the results of a previous study (36). Anandamide
and methanandamide both acted as partial agonists, in agreement with previous studies demonstrating partial agonism for
the inhibition of Ca21 currents (37) and adenylyl cyclase activity (38, 39). As previously shown (34, 35), D9-THC acted as a
weak partial agonist, stimulating only 20% of the [35S]GTPgS
binding of the full agonists. SR141716A appeared to be a neutral antagonist, although the decreased [35S]GTPgS binding at
10 mM SR141716A seemed to agree with other recent reports of
inverse agonism by SR141716A (51–53). However, since
SR141716A has a KD of 0.3 nM in brain membranes (41), it is
unlikely that inhibition of [35S]GTPgS binding was a CB1
receptor-mediated effect. If some CB2 receptors are present in
cerebellum (6), then the 700 nM Ki of SR141716A at CB2
receptors (54) makes it possible that this inhibitory effect was
mediated by CB2 receptors.
In agreement with results obtained in the mu opioid system,
increasing the concentration of GDP between 0.1 and 100 mM
increased efficacy differences among agonists (33). Significant
stimulation of [35S]GTPgS binding was observed only in this
range of GDP concentrations. The slight and variable stimulation of [35S]GTPgS binding observed in the absence (or at
nanomolar concentrations) of added GDP may have been due to
agonist-induced release of pre-bound GDP on the G-proteins
(43).
A question that can be addressed by these data is which
change in G-protein affinity is mediating agonist efficacy, i.e. is
an increase in GTP(gS) affinity the fundamental mechanism or
is the agonist-induced increase in apparent GTP(gS) affinity
caused by a decrease in GDP affinity? These data suggest that
the agonist-induced increases in the apparent affinity of
[35S]GTPgS were due to decreases in the affinity of GDP, since
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different from the anandamide compounds only at 100 mM GDP
(data not shown). The antagonist SR141716A was different
from all of the agonists at every GDP concentration assayed
with this ligand (1–100 mM).
Fig. 7 shows the correlation between agonist efficacy for the
stimulation of [35S]GTPgS binding (expressed as a percent of
levonantradol Emax) and agonist-induced GDP low affinity Ki
values (from Table IV). These data show that agonists of high
efficacy produced higher low affinity GDP Ki values than agonists of lower efficacy. The correlation between these two parameters was highly significant (r 5 0.979, analysis of variance, p 5 0.0007). In contrast, there was no significant
correlation (r 5 0.333, p 5 0.519) between Emax values and high
affinity GDP Ki values obtained in the presence of each agonist
(data not shown).
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these changes were observed only in the presence of added GDP
(Fig. 3 and Table II). Moreover, the agonist-induced
[35S]GTPgS affinities (measured with 30 mM GDP) and GDP
affinities were reciprocal, high affinity for [35S]GTPgS and low
affinity for GDP (Fig. 8). The two affinity states for [35S]GTPgS
(measured with 30 mM GDP) and GDP observed in the basal
state may also be reciprocal; the low affinity [35S]GTPgS-binding sites may correspond to the high affinity GDP-binding sites,
and basal binding also exhibited intermediate affinities for
both ligands (Fig. 3, lower panel, and Fig. 4; and Tables II and
III; and Fig. 8). The affinities of [35S]GTPgS for the three sites
observed in the presence of 30 mM GDP can actually be predicted based on the observed affinities for GDP and previous
reports of the actual affinity of purified Ga subunits for
[35S]GTPgS. This prediction was made on the basis that the
presence of a binding competitor will decrease the apparent
affinity of a radioligand by an amount proportional to the ratio
of the competitor’s concentration and inhibition constant, according to a rearrangement of the Cheng-Prusoff equation: KD
ratio 5 ([C]/Ki) 1 1, where KD ratio is the ratio of the apparent
KD and the actual KD for [35S]GTPgS in the presence and
absence of GDP, respectively; [C] is the concentration of GDP,
and Ki is the inhibition constant for GDP at each binding site.
Therefore, 30 mM GDP would shift the apparent [35S]GTPgS
affinity at each GDP-binding site (Ki values of 30, 1000, and
7000 nM; see Table III) by approximately 1000-, 30-, and 5-fold,
respectively. The apparent high affinity KD value of
[35S]GTPgS binding in the absence of added GDP was 3 nM, but
this value is probably higher than the actual KD of G-proteins
for [35S]GTPgS due to the presence of pre-bound GDP on Ga
(43). The actual KD value was probably less than 1 nM, as
previously reported for purified Goa (30), Gia (29), and Gsa (48).
If the affinity of [35S]GTPgS at membrane G-proteins was 0.5
nM, for example, the apparent affinities of these sites for
[35S]GTPgS in the presence of 30 mM GDP would be 500, 15,
and 2.5 nM, which are almost identical to the apparent KD
values measured in the present study, 540 –980, 14, and 4 nM
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FIG. 8. Proposed reciprocity of guanine nucleotide-binding
sites. The binding sites for [35S]GTPgS (when measured in the presence
of 30 mM GDP) and GDP that appear only in the presence of agonist
display affinities that are reciprocal, with [35S]GTPgS exhibiting high
apparent affinity and GDP exhibiting low affinity. The remaining binding sites that appear in the presence of agonist, which exhibit low
apparent affinity for [35S]GTPgS and high affinity for GDP, appear to
be present also in the absence of agonist, under basal conditions. The
binding sites for each ligand that are apparent only in the absence of
agonist both display intermediate affinities. Since the apparent affinities of [35S]GTPgS in the presence of GDP appear to depend on the
affinity for GDP, it suggests the possibility that each ligand binds to the
same three sites with reciprocal apparent affinities.

(Table II). Thus, it appears that the three apparent affinity
states of G-proteins for [35S]GTPgS can be explained in terms
of three affinity states for GDP. If all of the observed changes in
[35S]GTPgS binding affinity in the presence of GDP and/or
agonist can be explained in terms of competition by GDP with
three different affinities, then the apparent increases in
[35S]GTPgS binding affinity that were induced by agonist were
due to agonist-induced decreases in G-protein affinity for GDP.
This is in agreement with studies of purified Go indicating that
the primary mechanism of agonist activation is an increase in
the dissociation rate and a decrease in the association rate of
GDP (23). Moreover, the correlation between agonist-induced
Ki values and agonist Emax values (Fig. 7 and Table IV) indicates that the maximal ability of each agonist to stimulate
[35S]GTPgS binding is dependent on the degree of GDP release
induced by each agonist. This model is in agreement with a
previous study where mu opioid agonists were observed to
induce high affinity states for [35S]GTPgS that were proportional to their efficacy for stimulating [35S]GTPgS binding in
concentration-effect curves (33).
This model of agonist-induced GDP release also explains the
requirement for micromolar concentrations of GDP to observe
significant agonist effects in the [35S]GTPgS binding assay.
Addition of GDP has widely been observed to decrease basal
[35S]GTPgS binding more than agonist-stimulated binding
(Figs. 3 and 4), and the reason is now clear: G-proteins exhibit
a lower affinity for GDP in the presence of agonist (30 nM and
8 mM) than under basal conditions (30 nM and 1 mM). GDP is
only effective in the micromolar range because it must compete
at the intermediate and low affinity GDP-binding sites with
[35S]GTPgS, which exhibits nanomolar affinities for these
sites. Thus, in the absence of added GDP, [35S]GTPgS binds to
G-proteins regardless of the presence of agonist because there
is insufficient GDP to result in significant re-association to
either 1 or 8 mM affinity sites. In the presence of agonist, GDP
competes with [35S]GTPgS significantly better at unactivated
G-proteins than at agonist-activated G-proteins due to these
affinity differences, resulting in greater decreases in basal than
agonist-stimulated [35S]GTPgS binding.
These data do not provide direct evidence concerning the
source of the agonist-induced [35S]GTPgS-binding sites. However, it is clear that the agonist increases the apparent affinity
of [35S]GTPgS binding between 3- and 200-fold or more, depending on whether the high affinity (4 nM) sites were derived
from sites that displayed intermediate (14 nM) or low affinity
(800 nM) or for [35S]GTPgS binding under basal conditions.
Moreover, this study presents no direct evidence for the identity of the two basal binding sites observed for each ligand. It
may be that the basal intermediate affinity binding sites and
high affinity GDP-/low affinity [35S]GTPgS-binding sites represent receptor-coupled and non-coupled G-proteins, respectively, a concept that is currently being investigated by further
studies. However, a large portion of the total low affinity
[35S]GTPgS-binding sites may be non-G-protein sites such as
tubulin, guanylyl cyclase, or other nucleotide triphosphatases
(55).
Previous reports of the mechanisms of receptor activation of
purified G-proteins have found that agonists induced G-proteins to release GDP, allowing GTP or [35S]GTPgS to bind to
G-protein a subunits (15, 16, 23). Studies with adenosine receptors in membranes showed that the magnitude of agonistinduced release of [3H]GDP from membranes corresponded to
agonist efficacy (32). In the current study, experiments measuring the effect of different cannabinoid agonists on GDP binding affinities indicated that the mechanism of agonist efficacy
is the magnitude of the decrease in G-protein affinity for GDP.

Cannabinoid-stimulated [35]GTPgS Binding and GDP
These results explain why increases in GDP concentration
magnified differences in agonist efficacy in both the present
study and in the mu opioid system (33). Thus, the results of the
present study appear to generalize to G-protein-coupled receptors based on similarities to previously published results from
both purified and native membrane systems. It appears that
the agonist-induced low affinity state of the G-protein for GDP
is necessary and sufficient to explain agonist-induced stimulation of [35S]GTPgS binding by G-protein-coupled receptors.
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